JP2022535108A5 - - Google Patents

Info

Publication number
JP2022535108A5
JP2022535108A5 JP2021571941A JP2021571941A JP2022535108A5 JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5 JP 2021571941 A JP2021571941 A JP 2021571941A JP 2021571941 A JP2021571941 A JP 2021571941A JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5
Authority
JP
Japan
Application number
JP2021571941A
Other languages
Japanese (ja)
Other versions
JP2022535108A (ja
JPWO2020247418A5 (https=
JP7820152B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035808 external-priority patent/WO2020247418A1/en
Publication of JP2022535108A publication Critical patent/JP2022535108A/ja
Publication of JP2022535108A5 publication Critical patent/JP2022535108A5/ja
Publication of JPWO2020247418A5 publication Critical patent/JPWO2020247418A5/ja
Application granted granted Critical
Publication of JP7820152B2 publication Critical patent/JP7820152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571941A 2019-06-04 2020-06-03 キナーゼ依存性障害の処置のための化合物 Active JP7820152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856920P 2019-06-04 2019-06-04
US62/856,920 2019-06-04
PCT/US2020/035808 WO2020247418A1 (en) 2019-06-04 2020-06-03 Compounds for the treatment of kinase-dependent disorders

Publications (4)

Publication Number Publication Date
JP2022535108A JP2022535108A (ja) 2022-08-04
JP2022535108A5 true JP2022535108A5 (https=) 2023-06-12
JPWO2020247418A5 JPWO2020247418A5 (https=) 2023-06-12
JP7820152B2 JP7820152B2 (ja) 2026-02-25

Family

ID=71842789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571941A Active JP7820152B2 (ja) 2019-06-04 2020-06-03 キナーゼ依存性障害の処置のための化合物

Country Status (10)

Country Link
US (1) US12503438B2 (https=)
EP (1) EP3980404A1 (https=)
JP (1) JP7820152B2 (https=)
CN (1) CN114040912B (https=)
AR (1) AR119069A1 (https=)
AU (1) AU2020289324B2 (https=)
CA (1) CA3139156A1 (https=)
MA (1) MA56114A (https=)
TW (1) TWI850394B (https=)
WO (1) WO2020247418A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA128476C2 (uk) * 2018-01-26 2024-07-24 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−1(pd−1)に対する抗体
IL248408B (en) * 2014-04-25 2022-06-01 Exelixis Inc A method for treating adenocarcinoma of the lungs
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
SG11202005719UA (en) 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
UA128476C2 (uk) * 2018-01-26 2024-07-24 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2022535108A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016176A2 (https=)